Lv1
30 积分 2023-09-09 加入
A Patient with EGFR Exon 20 Insertion–Mutant Non–Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy
1个月前
已完结
Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status
5个月前
已完结
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
5个月前
已完结
Erythroderma and a Pulmonary Nodule
5个月前
已完结
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
8个月前
已完结
Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial
8个月前
已完结
The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy
9个月前
已完结
Proton pump inhibitors reduce nivolumab efficacy in unresectable advanced or recurrent gastric cancer
9个月前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
9个月前
已完结
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
1年前
已完结
皖公网安备34019202002308
